Effect of Androgel [testosterone gel] on inflammatory mediators and oxidative stress in type 2 diabetic males with hypogonadism.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Jan 2013
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 17 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Jun 2012 Planned End Date changed from 1 Jul 2010 to 1 Jul 2013 as reported by ClinicalTrials.gov.